This causes the cells to grow out of control. Like PIK3CA, HER2 is not an inherited gene mutation. Most breast cancer is HER2-negative. Research suggests about only 10% to 20% of cases are HER2 ...

In addition to genetic mutations, hormonal changes likely increase the risk of developing HR+/HER2- breast cancer. Several factors may increase the risk for HR+/HER2- breast cancer, including ...

If approved, trastuzumab rezetecan could provide a new option for the small percentage of patients whose tumors harbor HER2 mutations. An investigational antibody-drug conjugate proved active and ...

Boehringer's zongertinib and Bayer's BAY 2927088 are in phase 3 testing for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations, and the WCLC congress gave an opportunity to ...

The phase 1b BEAMION LUNG-1 trial reported a 71% objective response rate and favorable safety profile for zongertinib. HER2 mutations in NSCLC are linked to poor prognosis, affecting 2%-4% of cases, ...

The second thing that's emerged in the last six months is asking your oncologist, if you have a gene mutation called HER2. HER2 is something that oncologists know in terms of the breast cancer world, ...

Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Zongertinib is being reviewed for the treatment of adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have HER2 mutations and who have received prior systemic ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...